Optum Rx's latest look at the drug development pipeline highlights three drugs for rare and chronic conditions that payers and plan sponsors should have on their radar. | Optum Rx's latest look at the drug development pipeline highlights three drugs for rare and chronic conditions that payers and plan sponsors should be watching.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Healthcare costs continue to rise, making effective payer-provider collaboration more important than ever. Download this free…
The payer that waits is the payer that loses. Cognizant's 2026 research reveals how AI-assistable tasks across health plan…
Explore how AI, advanced analytics and real-world data can help identify rare disease patients earlier, reduce diagnostic delays…
LAS VEGAS — As drug costs and spending continue to rise, the demand for solutions opens the door to closer collaboration between…
Major health insurers saw positive signs in the second quarter, but the pressures they've faced over the past year haven't…
Drug spending is rising sharply, with high-cost GLP-1 medications driving nearly half of the incr | How RxSense helped a health…
